Cardiotoxicity clinical trials

Explore recruiting cardiotoxicity clinical trials.

Recruiting cardiotoxicity studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cardiotoxicity trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Sacubitril/Valsartan in PriMAry preventIoN of the cardiotoxicity of systematic breaST canceR trEAtMent. Randomized, multicenter, double-blind, placebo-controlled study.

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase II “proof of concept” Study, randomized 1:1, to evaluate whether dapagliflozin reduces chemotherapy induced cardiotoxicity in participants with breast cancer treated with (neo-) adjuvant Anthracycline-based chemotherapy +/- trastuzumab, study is national multicentered

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Prevention of cardiac Dysfunction during Adjuvant breast cancer therapy: A Randomized, Placebo-controlled, Multicenter Trial (PRADA-II)

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, placebo-controlled, double-blinded Phase 2 Trial of Dapagliflozin for Preventing Treatment-associated Cardiotoxicity in Lymphoma

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Epirubicin for the Treatment of Sepsis & Septic Shock

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Serial cardiac magnetic resonance imaging (CMR) with contrast agents and biomarker analysis for the detection of cardiotoxicity under anthracycline-containing cancer therapy - A monocentric, low interventional Phase IV pilot study

Germany

Therapeutic use (Phase IV) EU CTIS Study details

Cardiotoxicity trials by city

Cardiotoxicity in Toronto Cardiotoxicity in Vancouver Cardiotoxicity in Montreal Cardiotoxicity in Calgary Cardiotoxicity in Edmonton Cardiotoxicity in Ottawa Cardiotoxicity in Winnipeg Cardiotoxicity in Quebec City Cardiotoxicity in Hamilton Cardiotoxicity in Kitchener Cardiotoxicity in London Cardiotoxicity in Halifax Cardiotoxicity in New York Cardiotoxicity in Los Angeles Cardiotoxicity in Chicago Cardiotoxicity in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease